21st annual meeting of the consortium of ms centers

The Challenges of Care and Research in Multiple Sclerosis

May 30 - June 2, 2007 - Washington, DC, USA

• 3-1/2 days, 150 speakers, 1,397 learners, 40 commercial exhibitors, over 100 posters presented.
• Learner type: 8% Physicians, 9% Nurses, 2% Pharmacists, 3% Social Workers, 78% Other
• Credit type: ACCME, ANCC, ACPE and NASW.
• This year’s theme, The Challenges of Care and Research in Multiple Sclerosis provided attendees with information about the immunology, genetics, epidemiology, and pathophysiology of the disease, basic fundamentals of multiple sclerosis care, advanced concepts both in care and research, discussion about technology in the diagnosis and treatment of multiple sclerosis, addressing disease progression, and symptomatic and rehabilitative care.
• 94% of learners reported that the content was free from commercial bias.
• 96% of learners reported that the content was scientifically rigorous.
• 99% of learners reported that they would recommend this program to a colleague.
• 98% of learners reported the stated learning objectives were met.
• Objectives of the course were to:
• Describe current research into the etiology and pathogenesis of MS.
• Identify epidemiologic and genetic landmarks in MS.
• Cite effective ways of managing MS symptoms.
• Discuss rehabilitation strategies that are effective throughout the course of the disease.
• List new pharmacological and non-pharmacological methods of managing MS.
• Identify treatment options in patients with breakthrough disease.
• Explain the use of MRI in the diagnosis and management of MS.

• Selected learner comments included:

• “The program is very informative with up to date information and it is a great networking resource.”
• “Updated and breaking new information, multidisciplinary.”
• “New information being found with research.”
• “Comprehensive curriculum.”
• “Good source for CEUs, wealth of information.”
• “Presents cutting edge information on treatment and research in MS.”
• “It is always great to network with your peers and I am always amazed at the organization of the program.”
• “Current hot topics were thoroughly discussed.”
• “No matter what your level of expertise, there is always something to be learned from the program.”
• “Concentrated education specific to MS care from experts of all disciplines.”
• “Excellent faculty, wide variety of topics, evidence-based program.”
• “Lots of information, good review of information, meet people from throughout the world.”
• “Yes, I do recommend this yearly program for health professionals to update us and help network with others.”
• “Good basic but a bit repetitive in terms of topics and speakers.”
• “Program was very informative, I personally gained a better understanding of the disease, treatment and long term management of disability and resources available.”
• “This is the only truly interdisciplinary MS meeting. It is an invaluable meeting for those like myself whose clinical practice is solely focused on the care of MS patients.”
• “Excellent program – the best in the 18 years I have attended.”

• Selected comments about the speakers included:

• “All speakers did a nice job covering material – meeting objectives.”
• “Excellent presentation and speaking skills, most slides were effective. Topics were too advanced for me.”
• “Excellent videos in presentation.”
• “Excellent thorough presentation at the level of a non-neurologist.”
• “Information was interesting but not relevant to today – it seems like I have heard/read some of it before."
• “Very informative, speakers were knowledgeable.”
• “Patient cases were great.”
• “Too narrow of a topic – add neuropsych, OT, rehabilitation physician – to discuss all areas of disability determination.”
• “Very thorough with many excellent “take home” tips.”
• “Very informative and speakers qualified ‘this is what works for us, it may not be for everyone’.”
• “Enthusiastic, motivated speaker.”
• “AV problems in the morning and early afternoon were frustrating. Presenters did well regardless.”
• “More case presentations would be great.”
• “Excellent as usual. More audience involvement in case discussions would have made session more dynamic, interesting and relevant cases.”
• “Great speakers – very informative. Too bad this topic wasn’t longer.”
• “Very interesting studies and strategies that are attainable, comprehensive morning of information.”
• “Somewhat over my head but I’m not a researcher.”
• “Some presentations a little too basic.”
• “Very innovative presentation, raise consciousness of how serious an attack may be.”
• “Thank you for some real scientific and clinical competence.”
• “I very much appreciate the effort to explain at a non-immunologist level.”

Disclosure of Faculty Relationships

BioSymposia, Inc. (formerly Serono Symposia International, Inc.) adheres to guidelines of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA), the Accreditation Council for Pharmaceutical Education (ACPE), and all other professional organizations as applicable, stating that programs where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

As uses for pharmaceutical agents, medical devices, and other products may be presented in the program that are not necessarily the same as those indicated in approved product labeling (but which may reflect clinical experience, professional literature, other clinical sources known to the presenter, or investigational uses of products), we ask the presenter to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is simply intended to inform participants of any potential conflicts so that participants may form their own judgments based on full disclosure of the facts. Further, these opinions and recommendations presented during the program or materials related to the program do not imply an endorsement or recommendation on the part of BioSymposia, Inc. These presentations solely represent the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-FDA approved (off-label) uses of drugs:

 

Amit Bar-Or, M.D. FRCP(C) discloses he has received honoraria for speaking at meetings supported by, or consulting for Aventis, Bayhill Therapeutics, Berlex, Biogen Idec, Genentech, EMD Serono, Teva Neuroscience, BioMS and the Immune Tolerance Network/NIH.

 

Brenda Banwell, M.D. discloses that she will include off-label discussion of dosing and safety of immunomodulatory therapies in the pediatric population.

 

Jill Beavin, RN, BSN, MSCN is a member of a company-sponsored speaker’s bureau for Biogen Idec/Elan. Ms. Beavin will include off-label discussion of IVIgG and cyclophosphamide for MS patients.

 

Francois Bethoux, M.D. discloses that he is a member of a speaker’s bureau and he has received research grants and honoraria from Medtronic, Inc. Dr. Bethoux’s presentation will include off-label discussion of botulinum toxin and intrathecal baclofen for the treatment of spasticity in MS patients.

 

Patricia Bobryk, MHS, PT, MSCS discloses she has received honoraria from Berlex, EMD Serono, Teva Neuroscience, NMSS and CMSC.

 

Allen Bowling, M.D., Ph.D. will include off-label discussion of alternative therapies for treating multiple sclerosis.

 

Diego Cadavid, M.D. discloses he has received research grant support from Berlex.

 

Jonathan Calkwood, M.D. discloses he is a consultant for and has received research grants from Berlex/Bayer and EMD Serono. He also discloses he has received honoraria from Teva Neuroscience and Biogen Idec. Dr. Calkwood’s presentation will include off-label discussion of CAMPATH, chemotherapies, plasma exchange and IVIG in the treatment of MS patients.

 

Dorothea Cassidy Pfohl, RN, BS, MSCN will include off-label discussion of medications used to manage MS symptoms.

 

Tanuja Chitnis, M.D. is a consultant for Berlex and Teva Neuroscience. Dr. Chitnis’ presentation will include off-label discussion of immunmodulatory treatments used for the treatment of pediatric MS patients.

 

Patricia Coyle, M.D. discloses she is a consultant and speaker for Berlex, Biogen Idec, EMD Serono, Inc., Pfizer and Teva Neuroscience. She has received grants from Berlex, EMD Serono, Inc. and Teva Neuroscience.

 

Virginia Devonshire, M.D., FRCPC will include off-label discussion of tricyclic antidepressants and anti-convulsants for the treatment of MS pain. Dr. Devonshire also discloses she has received grants and speaker/advisory board honoraria from Berlex, Biogen Idec, EMD Serono, Teva Neuroscience and Valeant.

 

Suhayl Dhib-Jalbut, M.D. discloses he is a consultant for Berlex, EMD Serono and Teva Neuroscience. He has also received research grants from Teva Neuroscience.

 

Gilles Edan, M.D. discloses he has received compensation for serving on a scientific advisory board or for speaking from Biogen Idec, Bayer Health Care, Bayer Schering Pharma AG, LFB, EMD Serono and Sanofi-Aventis. He also discloses he has received research grants from EMD Serono and Sanofi-Aventis.

 

Anthony Feinstein, M.D. discloses he has received honoraria from Avanir Pharmaceuticals, EMD Serono Canada and Teva Neuroscience.

 

Cynthia Gibson-Horn, PT will include discussion of the use of an orthotic for balance improvement in MS patients. The product is in development and not for sale; research has been conducted and it is in prototype form.

 

Barbara Giesser, M.D. discloses she is a member of a speaker’s bureau for Berlex, EMD Serono, Pfizer and Teva Neuroscience. She is a consultant for Alza.

 

Danuta Gogol, CNS, NP, LPC, CLNC will include off-label discussion of medications used to manage spasticity in MS patients.

 

Douglas Goodin, M.D. discloses he has received research grant funding from Berlex/Schering/Bayer, Biogen Idec, EMD Serono/Pfizer, Novartis, and Teva Neuroscience. He also discloses he has received honoraria from Berlex/Schering/Bayer, EMD Serono/Pfizer, and Teva Neuroscience.

 

Colleen Harris, MN, NP, MSCN discloses she has received honoraria from Berlex/Bayer, EMD Serono, Biogen Idec and Teva Neuroscience. Ms. Harris’ presentation will include off-label discussion of medications used to manage MS symptoms.

 

Mary Hughes, M.D. discloses she is a member of a company sponsored speaker’s bureau for Berlex and EMD Serono, Inc.

 

Stephen Kamin, M.D. will include off-label discussion of immunomodulators and immunosuppressants in breakthrough disease.

 

Daniel Kantor, M.D. discloses he is a consultant or speaker for Bayer/Berlex, Biogen Idec, EMD Serono, Novartis, Pfizer, Questcor and Teva Neuroscience. He is a principal investigator for Novartis and Bayer studies.

 

Patricia Kennedy, RN, CNP, MSCN is a consultant and member of a speaker’s bureau for Berlex, Biogen Idec, EMD Serono, Pfizer, and Teva Neuroscience.

 

Sardar Khan, M.D. is a member of a company sponsored speaker’s bureau for Pfizer, Boehringer-Ingelhim and Lily.

 

George Kraft, M.D, MS discloses he will include off-label discussion of high dose immunosuppressive medications for immune suppression.

 

Judy Lane, M.D. discloses she is a member of a speaker’s bureau for GlaxoSmithKline, Merck, Forrest, Elan and Valeant. Dr. Lane will include off-label discussion of migraine preventive strategies.

 

Theresa LaRocca, RN, BSN, MSCN discloses she is a member of a company sponsored speaker’s bureau for Bayer Health Care Pharmaceuticals, Biogen Idec, EMD Serono, Pfizer and Teva Neuroscience.

 

Beverly Layton, RN, CCRC, MSCN will include off-label discussion of medications in clinical practice as part of “evidence based” practice and research. No specific medication will be discussed.

 

Tim Lotze, M.D. discloses he will include off-label discussion of the use of IMAs and other agents affecting immune function in the pediatric MS population. He also discloses he is a member of a company sponsored speaker’s bureau for Berlex and has a relationship with Pharma Frontiers.

 

Diane Lowden, MSc(A), MSCN discloses she is a member of an advisory board for Biogen Idec, Berlex Canada, EMD Serono, and Teva Neuroscience.

 

Heather MacLean, M.D., FRCP(C) discloses she has received honoraria from Biogen Idec, Berlex/Bayer, EMD Serono and Teva Neuroscience.

 

Clyde Markowitz, M.D. discloses he has received research grants, honoraria and is a consultant for Biogen Idec, Berlex, Genentech, EMD Serono, and Teva Neuroscience. He has received research grants from PDL, Opexa, and BioMS. Dr. Markowitz will include discussion of experimental trials in MS therapies.

 

Lynn McEwan, RN, MScN, MSCN discloses she has received honoraria for speaking, consulting and advisory committees from Berlex Canada, Biogen Idec, EMD Serono Canada, and Teva Neuroscience. She will include off-label discussion of medications used to treat tremors in MS patients.

 

M. Daniel McGowan, M.D., FRCP(c) discloses he received honoraria in June 2006 from Allergan.

 

Judith Anne Meyer PsyD discloses she is a member of a company sponsored speaker’s bureau for Teva Pharmaceutical.

 

Marie Namey, RN, MSN, MSCN discloses she will include off-label discussion of the use of medications used in the treatment of bladder function for MS patients.

 

Amy Perrin Ross, APRN, MSN, CNRN, MSCN discloses she has received honoraria from EMD Serono/Pfizer, Biogen Idec, Teva Neuroscience, Genentech and Berlex Laboratories. She is also a member of a company sponsored speaker’s bureau for EMD Serono/Pfizer, Biogen Idec, Teva Neuroscience, and Genentech.

 

Raymond Rackley, M.D. discloses he is a member of a company sponsored speakers bureau and is also a consultant for Pfizer, Novartis and Allergan. Dr. Rackley will include off-label discussion of outcome studies for botulinum toxin.

 

William Rooney, Ph.D. will include discussion of the use of MRI and contrast agents to study vascular properties.

 

Howard Rossman, DO discloses he has received honoraria and is a member of a company sponsored speaker’s bureau for Biogen Idec. He will also include off-label discussion of medications used in the treatment of cognitive issues experienced by MS patients.

 

Sonda Rossman, MA, LLPC discloses she has received honoraria and is a member of a company sponsored speaker’s bureau for Biogen Idec. She will also include off-label discussion of medications used in the treatment of cognitive issues experienced by MS patients.

 

Janet Rucker, M.D. will include off-label discussion of medications used to treat nystagmus.

 

Carol Saunders, BSN, BA, MSCN discloses she is a member of a speakers bureau for Berlex, Biogen-IDEC, EMD Serono, Teva Neuroscience, Questcor. Her presentation will include off-label discussion of immunotherapies used to treat MS patients.

 

Robert Shin, M.D. discloses he has received honoraria from Biogen Idec and Teva Neuroscience. Dr. Shin’s presentation will include off-label discussion of the use of MS medications for the treatment of CIS.

 

James Simsarian, M.D. discloses he is a member of a company sponsored speaker’s bureau and/or advisory board member for Biogen Idec, Berlex, EMD Serono, Genentech, Questcor, and Teva Neuroscience.

 

Jennifer Smrtka, MSN, ANP-BC, MSCN discloses she has received honoraria from Berlex Laboratories, Biogen Idec, EMD Serono, Pfizer, Teva Neuroscience, National MS Society and IOMSN. She also discloses she is a member of a company sponsored speaker’s bureau for Biogen Idec, EMD Serono, and Teva Neuroscience.

 

Peter Sonnenreich discloses he is a consultant for Teva Neuroscience.

 

Arnoldo Soto, M.D. discloses is a consultant for and has received research grants from Biogen Idec. He also discloses he is a member of a company sponsored speaker’s bureau for Merck-Serono and Schering-Bayer.

 

Pam Squire, M.D. discloses she has received honoraria from Bayer, Pfizer, Valeant, Janssen, Ortho, Ortho McNeil, Ortho Biotech, Purdue, GlaxoSmithKline, Merck Frosst, Proctor & Gamble, Astra Zeneca, and Paladin Laboratories. Dr. Squire’s presentation will include off-label discussion of medications used in the treatment of neuropathic pain in MS.

 

Matthew Sutliff, PT discloses he is a consultant for Geauga Rehabilitation Engineering and receives a royalty from the sale of HFAO.

 

Ben Thrower, M.D. discloses he is a speaker and research consultant for Acorda, Berlex/Bayer, EMD Serono, Inc., and Teva Neuroscience.

 

Anthony Traboulsee, M.D., FRCPC discloses he is a consultant for Bio MS and Bayhill. He also discloses he has received honoraria from Bayer Canada, honoraria and research grants from Teva Neuroscience Canada and EMD Serono Canada.

 

Herman Waldmann, FRS discloses he is a stockholder of TolerRx, Inc. and receives royalties from Genzyme. His presentation will include off-label discussion of the use of CD3 antibody in diabetes and alemtuzumab in multiple sclerosis.

 

Mark Ware M.D., FRCPC discloses he has received grants, cme support and consultancy fees/honoraria from Astra Zeneca, Bayer, Cannasat, GW Pharma, Solvay, and Valeant Pharmaceuticals. He also discloses he has received salary support from FRSQ, Edwards Foundation and grant support from CIHR, Hecht Foundation. Dr. Ware’s presentation will include discussion of medications used off-label in the treatment of pain in MS.

 

Brian Weinshenker, M.D. will include off-label discussion of plasma exchange therapy for CNS demyelinating disease. Dr. Weinshenker also discloses he is a consultant for Genentech, is the site PI for CAMPATH trial sponsored by Genzyme and owns intellectual property patent on neuromyelitis optica autoantigen for diagnosis of NMO.

 

Dean Wingerchuk, M.D. discloses he has received personal compensation for consulting from Genentech and he has received research support, paid to the Mayo Clinic, from the National MS Society.

 

Michael Yeung, M.D., FRCPC discloses he is a member of a company sponsored speaker’s bureau for Merck, GlaxoSmithKiline, Astra Zeneca, Pfizer, McNeil, Biogen Idec, Berlex/Bayer, Teva Neuroscience, EMD Serono, the National MS Society of Canada and the CMSC. He is also a member of the following company advisory boards: Merck, Biogen Idec, Berlex/Bayer, Teva Neuroscience and EMD Serono. Dr. Yeung has received research funding from Abbott, BioMS, Genentech, Sanofi-Aventis, Neurocrine, Amgen, Elan, Angiotech, Biogen Idec, Berlex/Bayer, Teva Neuroscience, PDL, GlaxoSmithKline, Pfizer and Novartis.

The following faculty indicated no significant relationship with commercial supporters and/or discussion of investigational or non-FDA approved (off-label) uses of drugs:

Alberto Ascherio, M.D., DrPH; Sergio Baranzini, Ph.D.; Anne Bateman, NP; Cathy-Lee Benbow, MSW, RSW; Susan Bennett, PT, EdD, NCS, MSCS; Aliza Ben-Zacharia, ANP; Christopher Bever, M.D., MBA; Gary Birnbaum, M.D.; Donna Jo Blake, M.D.; Dennis Bourdette, M.D.; Christina Caon, BSc, RN, MSN; Thaddeus Carlson, M.D., Ph.D. Student; Toni Chiara, PT, Ph.D.; Carol Chieffe, RN, MSCN, CCRC; Thomas Chippendale, M.D., Ph.D.; Jorge Correale, M.D.; Kristine Couch, OTR; Constance Easterling, MSN, ARNP, MSCN; David Engstrom, Ph.D.; Elizabeth Fisher, Ph.D.; Loren Fishman, M.D. B.Phil.; Frederick Foley, Ph.D.; Miriam Franco, LCSW, PsyD; Mark Freedman, M.D.; Donna Fry, PT, Ph.D.; Susan George, PT, MS; J.J. Geurts, Ph.D.; Eunice Gorman, RN, BSW, MSW; Erica Grazioli, D.O.; David Gruenwald, M.D.; June Halper, MSCN, ANP, FAAN; Michelle Harrison, PT; Jodie Haselkorn, M.D., MPH; Stephen Hauser, M.D.; Carrie Herman, PT, MS; Robert Herndon, M.D.; Cinda Hugos, MS, PT; Brian Hutchinson, PT, MSCS; Cynthia Irish, RN, MSCN; Rosalind Kalb, Ph.D.; Jason Kavountzis, MPT, CPT, OCS; Omar Khan, M.D.; Sarah Khan; Julia Klein, RN, MSN, FNPC, MSCN; Kimberly Koch, MPA; Karen Kott, Ph.D., PT; Mark Kroenke; Vijai Kumar, M.D.; John Kurtzke, M.D.; Sherie Lammers; Marco Lana-Peixoto, M.D.; Nicholas LaRocca, Ph.D.; Cornelia Laule, Ph.D.; Derrick Lee; Robert Lisak, M.D.; Thomas Mack, M.D., MPH; Anne Mageras; Terence McHale, PT, OCS; Michael McQuillen, M.D., MA; Catherine Meyer, RN; Deborah Miller, Ph.D.; David Mohr, Ph.D.; Dorothy Northrop, MSW; Jorge Oksenberg, Ph.D.; Margie O’Leary, RN, MSN, MSCN; Scott Patten, M.D., Ph.D.; Clara Pelfrey, Ph.D.; Lucinda Phair, RN, MA, MSCN; Sean Pittock, M.D.; Patricia Provance, PT, MSCS; Mary Elizabeth Quig, Ph.D.; Michael Racke, M.D.; Praveen Rao, Ph.D.; Nancy Richert, M.D. Ph.D.; Cindy Richman; Victor Rivera, M.D.; Lynn Rivers, PT, Ph.D.; A. Dessa Sadovnick, Ph.D.; Susan Sanabria; Randall Schapiro, M.D.; Bonnie Schaude, MA, CCC-SLP; Eileen Scheid, RN, MSN, MSCN, CCRC; Benjamin Segal, M.D.; Alan Segaloff; Jack Simon, M.D., Ph.D.; Stacey Sjoquist, PT; Eric Small; Christine Smith, OTR/L, MSCS; Dustin Sordelett; Shannon Stapleton, MSW, LICSW; Lael Stone, M.D.; Alexa Stuifbergen, Ph.D., RN, FAAN; Cynthia Sullivan, Ph.D.; Aaron Turner, Ph.D.; Tracy Walker, RN, CWOCN, FNP-C; Mitchell Wallin, M.D., MPH; Patti Webber, RN, BSN; Jeffrey Wilken, Ph.D.; Roberta Winter, MSW, LCSW, MSCS; Winston Wong, PharmD; Vijayshree Yadav, M.D.

 

Platform Presentations

P01 L.J. Balcer has received support for consulting on the development of visual outcome measures for multiple sclerosis clinical trials from Biogen Idec, Centocor, EMD Serono, Incyte, and Novartis. R.A. Rudick has no financial relationships to disclose. C.H. Polman has received consulting fees from Biogen Idec, Schering AG, Teva Pharmaceuticals, EMD Serono, Novartis Pharmaceuticals, GlaxoSmithKline, and Antisense Therapeutics; lecture fees from Biogen Idec, Schering AG, and Teva Pharmaceuticals; and grant support from Biogen Idec, Schering AG, Wyeth, Novartis Pharmaceuticals, and GlaxoSmithKline. J.A. Cohen received consulting fees from Biogen Idec, Eisai, Genentech, Genzyme, IMPAX, Incyte, Merck, Millenium, Novartis, Schering Plough, EMD Serono, Toray and Wyeth; and research support for clinical trials from Artielle, Biogen Idec, Immune Response Corporation, Novartis, and Teva Neuroscience. C. Confavreux has received consulting and lecture fees from Biogen Idec, Sanofi-Aventis, Schering AG, EMD Serono, and Teva. M. Hutchinson has received consulting fees from Biogen Idec and grant support from EMD Serono, Schering AG, and Biogen Idec. F.D. Lublin received research grant support from Biogen Idec, Teva, Acorda, and Merck and consulting/lecture fees from Biogen Idec, Berlex, Teva, Novartis, Schering Plough, EMD Serono, Pfizer, Amgen, and Antisense Therapeutics. A. Miller has received personal compensation for speaking or consulting from Abbott, Berlex, Biogen Idec, GlaxoSmithKline, Pfizer, Sanofi-Aventis, EMD Serono, Teva Neuroscience, UCB, and Accordant Health Services; and grant support for research activities from Acorda, Immune Tolerance Network and Teva Neuroscience. P.W. O’Connor has served as a consultant for and received research trial grant support from Biogen Idec. S.R. Schwid has received consulting fees from Novartis, EMD Serono; honoraria for speaking from Berlex, Biogen Idec, Pfizer, EMD Serono, and Teva Neuroscience; and research support from Acorda, Genentech, Merck, and EMD Serono. F. Lynn and M.A Panzara have equity interests and are employees of Biogen Idec.

 

P02 J. Cabrera-Gomez, A. González-Quevedo, Y. Real-Gonzàlez, D. Grss-Fernández, M. Cristòfol-Corominas, M.A. Robinson-Agramonte, K. Romero-García, M.L. Rodríguez-Cordero, R. Rodríguez-Roca, R. Lara-Rodríguez, I. Pérez-Chong, A.Y. Cabrera-Núnez, M. Oduardo, M. Rivas-Victor have nothing to disclose.

 

P03 L. Kappos has received financial support for research activities from Biogen Idec, Boehringer Ingelheim, Centocor, Eisai, Genzyme, GlaxoSmithKline, Novartis, Roche, Sanofi Aventis, Schering AG, EMD Serono, Teva, UCB and Wyeth. R. Gold has received grant support, speaker's honoraria and consulting fees from Biogen Idec, Schering AG, EMD Serono, and Teva. D. Miller received honoraria from Biogen Idec, GSK, Schering, UCB Pharma, and Wyeth for consulting, serving on a scientific advisory board, or speaking; reimbursement for work as co-chief editor, Journal of Neurology; and research grant support for MRI analysis of MS trials from Biogen Idec, GSK, and Schering. E. Havrdova participated in and was paid for clinical studies organized by Biogen Idec, Novartis, Octpharma, Schering, EMD Serono, and Teva; and received honoraria for lectures at symposia organized by Biogen Idec, Pfizer, Schering, and Teva. V. Limmroth has received personal compensation for serving on a scientific advisory board and speaking from Biogen Idec and other companies. C. Polman has received speaker's honoraria and consulting fees from Antisense, Biogen Idec, GlaxoSmithKline, Novartis, Schering, EMD Serono, and Teva; and research support for activities related to clinical trials from Biogen Idec, GlaxoSmithKline, Novartis, Schering, and EMD Serono. M. Yang and K. Dawson are employees of Biogen Idec, Inc. and hold stock in the company. G. O'Neill is an employee of Biogen Idec, Inc. and has received personal compensation for serving on a board of directors. M. Eraksoy, D. MacManus, E. Meluzinova, I. Rektor, K. Schmierer, and T. Yousry have nothing to disclose.

 

P04 L. Kappos discloses that the University Hospital Basel has received research support from Biogen Idec, GlaxoSmithKline, Novartis Pharmaceuticals, Sanofi-Aventis, Schering, EMD Serono, Teva Pharmaceuticals, and Weyth Pharmaceuticals. Prof. Kappos has been principal investigator, member, or chair of steering committees or advisory boards in MS clinical trials sponsored by Abbott Laboratories, Bayer, Bayhill, Berlex, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Centocor, Eisai, Elan Pharmaceuticals, Genzyme, GlaxoSmithKline, Immune Response, Neurocrine, Novartis Pharmaceuticals, Sanofi-Aventis, Schering, EMD Serono, Rocha, Teva Pharmaceuticals, UCB Pharma, and Wyeth, and has received lecture fees from one or more of these companies. Payments and consultancy fees have been exclusively used for the support of research activities. C.H. Polman has received consulting fees from Biogen Idec, Schering AG, Teva Pharmaceuticals, EMD Serono, Novartis Pharmaceuticals, GlaxoSmithKline, and Antisense Therapeutics; lecture fees from Biogen Idec, Schering AG, and Teva Pharmaceuticals; and grant support from Biogen Idec, Schering AG, Wyeth, Novartis Pharmaceuticals, and GlaxoSmithKline. D. Bates has received honoraria and research support from Biogen Idec, EMD Serono, Schering and Teva Pharmaceuticals. S.L. Hauser has received a research grant from Biogen Idec for neurogegenerative disease research. R.A. Rudick has no relationships to disclose. H.L. Weiner has received consultancy fees from Autoimmune, Biogen Idec, Pepgen, Pfizer, EMD Serono, Teva Pharmaceuticals, and Vascular Biogenics. P.W. O’Connor has served as a consultant for and received research trial grant support from Biogen Idec. J. King has received honoraria and consultancy fees from Biogen Idec, Sanofi-Aventis, Schering and EMD Serono. E.W. Radue has no relationships to disclose. T.A. Yousry received support to perform MRI analyses through a research grant from Biogen Idec to the Institute of Neurology. D.B. Clifford has received payment as a consultant by Biogen Idec, Genzyme, Millennium, Pfizer, and Schering-Plough, and as a speaker by Boehringer-Ingelheim and Bristol-myers Squibb. Dr. Clifford has received research support from Bararian Nordic, NeurogesX, Pfizer, Roche, Savient Pharmaceuticals and Tibotec.

 

P05 L. Kappos discloses that the University Hospital Basel has received research support from Biogen Idec, GlaxoSmithKline, Novartis Pharmaceuticals, Sanofi-Aventis, Schering, EMD Serono, Teva Pharmaceuticals, and Weyth Pharmaceuticals. Prof. Kappos has been principal investigator, member, or chair of steering committees or advisory boards in MS clinical trials sponsored by Abbott Laboratories, Bayer, Bayhill, Berlex, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Centocor, Eisai, Elan Pharmaceuticals, Genzyme, GlaxoSmithKline, Immune Response, Neurocrine, Novartis Pharmaceuticals, Sanofi-Aventis, Schering, EMD Serono, Roche, Teva Pharmaceuticals, UCB Pharma, and Wyeth, and has received lecture fees from one or more of these companies. Payments and consultancy fees have been exclusively used for the support of research activities. P.W. O’Connor has served as a consultant for and received research trial grant support from Biogen Idec. A. Goodman received personal compensation as a consultant or for speaking from Biogen Idec, Berlex, EMD Serono/Pfizer, Teva, Genzyme, and UCB, and received research grant support from Biogen Idec/Elan, Berlex, EMD Serono, Teva and Acorda. F.D. Lublin received research grant support from Biogen Idec, Teva, Acorda, and Merck and consulting/lecture fees from Biogen Idec, Berlex, Teva, Novartis, Schering Plough, EMD Serono, Pfizer, Amgen, and Antisense Therapeutics. D.H. Miller has received grant support from Biogen Idec, Elan, Schering, and GlaxoSmithKline for performance of MRI analyses in clinical trials, as well as honoraria for advisory or consultancy work, lectures, and related travel expenses from Aventis, Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Schering, EMD Serono, UCB Pharma, and Wyeth. C. Polman has received consulting fees form Biogen Idec, Schering AG, Teva Pharmaceuticals, EMD Serono, Novartis Pharmaceuticals, GlaxoSmithKline, and Antisense Therapeutics; lecture fees from Biogen Idec, Schering AG, and Teva Pharmaceuticals; and grant support from Biogen Idec, Schering AG, Wyeth, Novartis Pharmaceuticals, and GlaxoSmithKline. R.A. Rudick has no financial relationships to disclose. E. Fisher received financial support for clinical trial research activities from Biogen Idec and Millennium Pharmaceuticals. F. Lynn and M.A. Panzara have equity interests and are employees of Biogen Idec.

 

P06 J. Herbert received consultant fees from Biogen Idec, Teva Neuroscience and Berlex, Inc.

 

P07 W. Culpepper, W. Royal, M. Wallin, and D. Bradham have no financial interest to disclose.

 

P08 Y.Harris, S. Middleton, K. Bashir and J. Ness have nothing to disclose.

 

P09 C. Hunter, K. Johnson and R. Fraser have nothing to disclose.

 

P10 A. Stuifbergen, A. Brown, and L. Phillips received salary support from the National Institutes of Health during this research project and NIH support for data collection.

 

P11 M. Trisolini and J. Maier received salary support from NMSS contract with our employer, Research Triangle Institute that supports this research.

 

P12 C. White, M. White and C. Russell have nothing to disclose.

 

P13 J. Herbert received consultant fees from Biogen Idec, Berlex and TEVA pharmaceuticals. J. Bacon, J. Fromm, M. Adelman and R. Neuhaus have nothing to disclose.

 

P14 K. Dieruf has nothing to disclose.

 

P15 F. Foley, V. Zemon, D. Campagnolo, M. Devitt, T. Tyry, R.A. Marrie, G. Cutter, M.L. Sipski, T. Vollmer and V. den Burgh have nothing to disclose.

 

P16 K. Turpin, S.A. Warren, D.L. Milke, K.G. Warren, J. Christopherson, and T. Rust have nothing to disclose.

 

P17 F. Cáceres and S. Vanotti received a grant from Biogen Idec and Abbott Laboratories Argentina. R. Benedict and L. Acion have nothing to disclose.

 

Commercial Support and Other Disclosures

 

BioSymposia, Inc. (formerly Serono Symposia International, Inc.) is a 501(c)3 non-profit organization. All of our programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers and do not represent an endorsement or recommendation on the part of BioSymposia, Inc.

This program was supported by an unrestricted educational grant from Acorda Therapeutics, Bayer Healthcare Pharmaceuticals, Biogen Idec, EMD Serono, Inc., Pfizer, Genentech and Teva Neuroscience. In addition, BioSymposia personnel are employees of EMD Serono, Inc. and BioSymposia, Inc. also receives other in-kind support from EMD Serono, Inc. in the form of space and administrative services.

 

Printer friendly version 21st Annual CMSC Meeting